Therapy
The novel tubulin-binding agent ZD6126 seeks out vascular cells
Published in Cancer Weekly, May 20th, 2003
According to recent research published in the journal Cancer Research, "the tubulin-binding agent ZD6126 is a novel vascular-targeting agent in clinical development for the treatment of solid tumors. In vivo, ZD6126 is rapidly converted into N-acetylcolchinol (ZD6126 phenol). In this study, we have explored the antivascular property of N-acetylcolchinol in vitro and ZD6126 in vivo."
"In cell culture, N-acetylcolchinol induced rapid changes in the morphology of human umbilical vein and lung microvessel endothelial cells. Within 40 minutes, the compound induced endothelial cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-05-20)
More Articles from Cancer Weekly
- Kidney Cancer
Scientists report discovery of cancer-causing gene in childhood kidney tumor - Oncogenes
Myc binds to 10% of all genes - Dietary Anticarcinogens
Curcumin has great potential for prevention and therapy of cancer - Immunology
Scientists develop colony of mice that fight off virulent cancer - Prostate Cancer
Metastatic disease common, deadly and costly, multicenter study shows - Acute Lymphoblastic Leukemia
Stratification of patients by minimal residual disease results may be useful - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
